CA2396596A1 — Tetrahydropyrimidone inhibitors of fatty acid binding protein and method
Assigned to Bristol Myers Squibb Co · Expires 2001-08-02 · 25y expired
What this patent protects
aP2 inhibiting compounds are provided having formula (I) wherein A, B, X, and Y are as described herein. A method is also provided for treating diabetes and related diseases, especially Type II diabetes, employing such aP2 inhibitor or a combination of such aP2 inhibitor and anot…
USPTO Abstract
aP2 inhibiting compounds are provided having formula (I) wherein A, B, X, and Y are as described herein. A method is also provided for treating diabetes and related diseases, especially Type II diabetes, employing such aP2 inhibitor or a combination of such aP2 inhibitor and another antidiabetic agent such as metformin, glyburide troglitazone and/or insulin.
Drugs covered by this patent
- Brenzavvy (BEXAGLIFLOZIN) · Theracosbio
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.